FDA MedWatch - L.G Compounded Asafoetida Powder by Shakti Group: Recall - Potential Contamination with Salmonella

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

 



Title: FDA MedWatch - L.G Compounded Asafoetida Powder by Shakti Group: Recall - Potential Contamination with Salmonella
MedWatch logoMedWatch - The FDA Safety Information and Adverse Event Reporting Program

L.G Compounded Asafoetida Powder by Shakti Group: Recall - Potential Contamination with Salmonella

AUDIENCE: Consumer

ISSUE: Shakti Group USA LLC is recalling 50 gm and 100 gm sizes of L.G Compounded Asafoetida Powder, both coded with Lot Number: 2323 because it has the potential to be contaminated with Salmonella, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems.

The recall is a result of sampling conducted by the FDA which revealed that the finished products contained the bacteria.

Healthy persons infected with Salmonella often experience fever, diarrhea (which may be bloody), nausea, vomiting and abdominal pain. In rare circumstances, infection with Salmonella can result in the organism getting into the bloodstream and producing more severe illnesses such as arterial infections (i.e., infected aneurysms), endocarditis and arthritis. See the Press Release for product photos

BACKGROUND: L.G COMPOUNDED ASAFOETIDA POWDER was distributed to OH, NJ, VA, NH, and PA through retail stores.

The product is packaged in a white screw cap plastic bottle with UPC 840222000149, Lot Number: 2323.

RECOMMENDATION: Consumers who have purchased L.G COMPOUNDED ASAFOETIDA POWDER are urged to return it to the place of purchase for a full refund. Consumers with questions may contact the company at 1-609-357-9181 between the hours of 8am - 5pm EST from Monday - Saturday.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:

Read the MedWatch safety alert, including a link to the firm press release, at:

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm480984.htm

 


This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 1-888-INFO-FDA (1-888-463-6332) Powered by GovDelivery

[Index of Archives]     [CDC News]     [NIH News]     [USDA News]     [Steve's Art]     [Camping in Yosemite]     [PhotoForum]     [SB Lupus]     [STB]

  Powered by Linux